Business
Adagio Medical is a medical device company developing catheter-based ultra-low-temperature ablation technology for cardiac arrhythmias, initially ventricular tachycardia.
Adagio cut its net loss and drew CEO/CFO buying, but revenue fell to zero and cash burn worsened.
The read at a glance✓ Audited against SEC data
- Business mix — Ultra-low-temperature cardiac ablationNote
- Revenue — Revenue fell to $0Watch
- Profitability — Net loss improved to $25.1MOK
- Cash burn — Free cash flow was -$19.4MWatch
- Balance sheet — Equity -37.7% to $12.4MWatch
- Insiders — 2 buys / 0 sells; $244K boughtOK
- Accounting — Altman-Z distressWatch
Leadership changes
From Adagio Medical Holdings, Inc.'s own filings, the day they're filed.
- Deborah Kaster · Chief Financial Officer · appointmenteff. 2025-09-05
- Daniel George · Chief Financial Officer · appointmenteff. 2025-04-17
- John Dahldorf · Chief Financial Officer · departureeff. 2025-03-21
Latest filings
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-06-16
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Adagio Medical Holdings, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.